Adcendo, a clinical-stage biotechnology company developing ADCs for cancer treatment, has raised $75m in a Series C funding round.

Off the back of J&J's positive Q1, CEO Joaquin Duato forecasts strong growth acceleration for 2026, driven partially by psoriasis med Icotyde ...

Amazon has already collaborated with Memorial Sloan Kettering Cancer Center with its AI drug discovery software.

The FDA's guidance emphasises the potential of NGS methods to mitigate safety risks associated with therapies incorporating genome editing.

Eli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash.

An analyst noted that this uptick may be a case of “frontloading”, meaning the EU’s 2026 pharma export growth outlook may not be as strong.

Leading pharmaceutical industry players will convene at PHARMAP Congress 2026 on 20-21 April in the Netherlands, bringing together experts from manufacturing and packaging to quality assurance and ...

Novo Nordisk inks this deal with OpenAI as the total value of AI partnerships took a 120% YoY uptick between 2024 and 2025.

Travere Therapeutics has received FDA approval for Filspari to reduce proteinuria in patients aged eight years and over with FSGS without nephrotic syndrome.

The FDA has issued a complete response letter to Replimune’s biologics license application concerning the RP1 therapy.

Telix and Regeneron have entered a partnership for the development and commercialisation of new radiopharmaceutical therapies.

AbbVie's deal with Haisco comes as many pharma companies look to restock their pipelines amid looming global patent expiries.